Evercore Wealth Management buys $25,730,112 stake in Core Laboratories N.V. (CLB)

Core Laboratories N.V. (CLB) : Evercore Wealth Management scooped up 3,062 additional shares in Core Laboratories N.V. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 226,717 shares of Core Laboratories N.V. which is valued at $25,730,112.Core Laboratories N.V. makes up approximately 1.11% of Evercore Wealth Management’s portfolio.

Other Hedge Funds, Including , Aberdeen Asset Management Plcuk reduced its stake in CLB by selling 9,999 shares or 14.7% in the most recent quarter. The Hedge Fund company now holds 58,039 shares of CLB which is valued at $6,586,846. Core Laboratories N.V. makes up approx 0.02% of Aberdeen Asset Management Plcuk’s portfolio.Btr Capital Management Inc reduced its stake in CLB by selling 3,260 shares or 29.92% in the most recent quarter. The Hedge Fund company now holds 7,635 shares of CLB which is valued at $954,375. Core Laboratories N.V. makes up approx 0.21% of Btr Capital Management Inc’s portfolio. Kistler-tiffany Companies sold out all of its stake in CLB during the most recent quarter. The investment firm sold 100 shares of CLB which is valued $12,106.

Core Laboratories N.V. opened for trading at $112.91 and hit $114.38 on the upside on Thursday, eventually ending the session at $113.82, with a gain of 0.29% or 0.33 points. The heightened volatility saw the trading volume jump to 7,54,013 shares. Company has a market cap of $5,020 M.

On the company’s financial health, Core Laboratories N.V. reported $0.35 EPS for the quarter, based on the information available during the earnings call on Jul 20, 2016. Analyst had a consensus estimate of $0.35. The company had revenue of $148.10 million for the quarter, compared to analysts expectations of $146.21 million. The company’s revenue was down -27.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.81 EPS.

Many Wall Street Analysts have commented on Core Laboratories N.V.. JP Morgan Initiated Core Laboratories N.V. on Jun 10, 2016 to “Overweight”, Price Target of the shares are set at $120.

Core Laboratories N.V. (Core Lab) is a provider of proprietary and patented reservoir description production enhancement and reservoir management services to the oil and gas industry. These services and products are directed toward enabling its clients to improve reservoir performance and increase oil and gas recovery from their producing fields. The Company operates in three segments: Reservoir Description Production Enhancement and Reservoir Management. The Company provides analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.

Leave a Reply

Core Laboratories N.V. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Core Laboratories N.V.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.